US 12,290,529 B2
Methods of administering safe colon cleansing compositions
Edmund V. Dennett, Walpole, MA (US); Mark Cleveland, Norwell, MA (US); Russell W. Pelham, Duxbury, MA (US); and Matthew Walker, Brighton, MA (US)
Assigned to Braintree Laboratories, Inc., Braintree, MA (US)
Filed by Braintree Laboratories, Inc., Braintree, MA (US)
Filed on Aug. 2, 2024, as Appl. No. 18/792,849.
Application 18/792,849 is a continuation of application No. 18/743,526, filed on Jun. 14, 2024, granted, now 12,239,659.
Claims priority of provisional application 63/521,314, filed on Jun. 15, 2023.
Prior Publication US 2024/0415876 A1, Dec. 19, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/765 (2006.01); A61K 9/08 (2006.01); A61K 33/04 (2006.01); A61K 47/02 (2006.01); A61K 47/26 (2006.01); A61P 1/10 (2006.01)
CPC A61K 31/765 (2013.01) [A61K 9/08 (2013.01); A61K 33/04 (2013.01); A61K 47/02 (2013.01); A61K 47/26 (2013.01); A61P 1/10 (2018.01)] 3 Claims
 
1. A colon cleansing product comprising:
(a) a first container comprising a first portion of a first dose of a colon cleansing product comprising about 178.7 grams of polyethylene glycol 3350, about 7.3 grams of sodium sulfate, about 1.12 grams of potassium chloride, about 0.9 grams of magnesium sulfate, 0.5 grams of sodium chloride;
(b) a second container comprising a second portion of the first dose of a colon cleansing product comprising malic acid and citric acid;
(c) a third container comprising a first portion of a second dose of the colon cleansing product comprising about 178.7 grams of polyethylene glycol 3350, about 7.3 grams of sodium sulfate, about 1.12 grams of potassium chloride, about 0.9 grams of magnesium sulfate, about 0.5 grams of sodium chloride; and
(d) a fourth container comprising a second portion of the second dose of the colon cleansing product comprising malic acid and citric acid,
wherein the colon cleansing product further comprises lemon-lime flavor, sucralose, and neotame; and
wherein the colon cleansing product is formulated so that the combination of the first dose and second dose cleanse a colon of a subject without causing a sodium balance of −50.00 mEq/L or greater in the subject.